Drug Trials Snapshots: POMBILITI

Why It Matters

POMBILITI expands therapeutic options for a rare, progressive muscle‑wasting disorder, addressing a gap for patients who fail current enzyme therapies and potentially reshaping the LOPD treatment landscape.

Key Takeaways

• FDA approved POMBILITI for adult LOPD patients ≥40 kg.
• Trial 1 enrolled 123 patients across 61 sites in 24 countries.
• POMBILITI + Opfolda improved FVC % predicted versus comparator.
• Most common adverse events: headache, diarrhea, fatigue, nausea, fever.
• Subgroup analysis limited; safety profile similar across sexes and ages.

Pulse Analysis

Late‑onset Pompe disease (LOPD) remains a therapeutic challenge, affecting roughly 1 in 40,000 individuals and leading to progressive respiratory decline. Traditional enzyme replacement therapy (ERT) can stabilize disease but often fails to halt lung function loss in a subset of patients. POMBILITI, a recombinant human acid alpha‑glucosidase, is engineered to enhance cellular uptake and glycogen clearance, offering a novel mechanism when paired with the oral chaperone Opfolda. This combination targets the underlying enzymatic deficiency while stabilizing the enzyme, positioning it as a differentiated option in a niche market.

The pivotal Phase III trial enrolled 123 adults across 61 global sites, comparing POMBILITI + Opfolda to an active comparator over 52 weeks. Patients receiving the new regimen demonstrated a mean change of +0.1 percentage points in FVC, versus a –3.5‑point decline with the comparator, translating to a statistically significant 3.5‑point advantage (95 % CI 1.0‑6.0). Subgroup analyses hinted at greater benefit in females, though the sample size limited definitive conclusions. While the efficacy signal is modest, preserving lung capacity is clinically meaningful for LOPD patients whose quality of life hinges on respiratory function.

Safety findings were reassuring, with serious infusion‑related reactions rare and most adverse events—headache, diarrhea, fatigue, nausea, fever—occurring in less than 10 % of participants. The comparable safety profile across sexes and age groups supports broader adoption. Market-wise, POMBILITI enters a space dominated by a few legacy ERTs, offering a potential premium due to its combination strategy. Payers will scrutinize cost‑effectiveness, but the drug’s ability to address an unmet responder population could drive uptake, especially as real‑world data emerge from the ongoing open‑label extension.